Stanford Cancer Institute
Translating Stanford discoveries into individualized cancer care
ASH President-Elect: A Look Back on the Path That Led Him Here
In 2023, SCI member Rob Negrin was elected president of the American Society of Hematology after over 25 years of service to the organization.
SCI Fellowship Awards
Congratulations to the 2024 SCI Fellowship awardees. Explore their outstanding projects.
CAR-T Cell Therapy in Solid Tumors
CAR-T therapy has shown a great benefit in patients with hematologic and lymphatic cancers. However, applying the therapy to solid tumors has proven to be challenging. One of the barriers is T cell exhaustion, where the CAR-T cell becomes dysfunctional.
The Future of Cancer
The SCI is focused on pushing the limits of what we can do and what we know. The only way to really advance our knowledge is to push forward in laboratories, keep thinking about novel approaches, novel mechanisms. We cannot stand still!
National Cancer Institute Designation
The Stanford Cancer Institute has been designated a Comprehensive Cancer Center by the National Cancer Institute, a part of the National Institutes of Health and the world’s leading cancer research organization.
Designation as a Comprehensive Cancer Center signifies that the Stanford Cancer Institute maintains the highest level of scientific rigor, institutional support and coordination for the complete range of cancer-related research, including basic, translational, clinical and population-based science. The designation is recognition of the institute’s robust and integrated programs encompassing laboratory research, clinical care and community outreach and education.
The Institute’s mission is to support and coordinate the wide range of cancer-related activities — in basic, translational, clinical and population-based science — occurring at Stanford University, Stanford Health Care and Lucile Packard Children’s Hospital Stanford. Its over 450 members include scientists and physicians from a wide range of disciplines, all collaborating to translate research advances into improved cancer treatments.
-
Diabetes and liver cancer — Stanford Medicine study suggests new screening guidelines
A Stanford Medicine study identifies an easily measured biophysical property that can identify Type 2 diabetics at increased risk for liver cancer who don’t meet current screening guidelines.
-
Metastatic breast cancer treatments have aided decline in deaths, Stanford Medicine-led study finds
Treatment of metastatic disease is responsible for nearly one-third of the decrease in annual deaths from breast cancer from 1975 to 2019, according to a Stanford Medicine-led study.
-
Hodgkin lymphoma prognosis, biology tracked with circulating tumor DNA
Circulating tumor DNA predicts recurrence and splits disease into two subgroups in Stanford Medicine-led study of Hodgkin lymphoma. New drug targets or changes in treatments may reduce toxicity.
-
Scar tissue holds hints about pancreatic cancer outcome, Stanford Medicine-led research finds
Pancreatic cancer is deadly, and its toll is growing. Scientists find that scar tissue around the tumor suggests how long a patient will live after diagnosis.
Cancer Clinical Trials
Stanford Cancer Institute offers leading edge research and compassionate care with over 250 actively recruiting clinical trials, investigating a broad spectrum of new diagnostic, prevention and treatment strategies.